Tiippana Elina, Nelskylä Kaisa, Nilsson Eija, Sihvo Eero, Kataja Matti, Kalso Eija
Helsinki University Central Hospital, Department of Anaesthesia, Intensive Care Medicine, Emergency Medicine and Pain Medicine, Helsinki, Finland.
Helsinki University Central Hospital, Department of Surgery, Helsinki, Finland.
Scand J Pain. 2014 Oct 1;5(4):240-247. doi: 10.1016/j.sjpain.2014.07.001.
Background and aims Thoracotomies can cause severe pain, which persists in 21-67% of patients. We investigated whether NSAID + intravenous patient-controlled analgesia (IV-PCA) with morphine is an efficacious alternative to thoracic epidural analgesia (TEA). We also wanted to find out whether an extended controlled pain management protocol within a clinical study can decrease the incidence of persistent post-thoracotomy pain. Methods Thirty thoracotomy patients were randomized into 3 intervention groups with 10 patients in each. G1: preoperative diclofenac 75mg orally+150 mg/24h IV for 44h, then PO; G2: valdecoxib 40mg orally+parecoxib 80mg/24h IV for 44h, then PO. IV-PCA morphine was available in groups 1 and 2 during pleural drainage, and an intercostal nerve block at the end of surgery was performed; G3: parac-etamol+patient controlled epidural analgesia (PCEA) with a background infusion of bupivacaine with fentanyl. After PCA/PCEA oxycodone PO was provided when needed. These patients were contacted one week, 3 and 6 months after discharge. Patients (N = 111) not involved in the study were treated according to hospital practice and served as a control group. The control patients' data from the perioperative period were extracted, and a prospective follow-up questionnaire at 6 months after surgery similar to the intervention group was mailed. Results The intended sample size was not reached in the intervention group because of the global withdrawal of valdecoxib, and the study was terminated prematurely. At 6 months 3% of the intervention patients and 24%ofthe control patients reported persistent pain (p<0.01). Diclofenac and valdecoxib provided similar analgesia, and in the combined NSAID group (diclofenac+valdecoxib) movement-related pain was milder in the PCEA group compared with the NSAID group. The duration of pain after coughing was shorter in the PCEA group compared with the NSAID+IV-PCA group. The only patient with persistent painat6 months postoperatively had a considerably longer duration ofpain after coughing than the other Study patients. The patients with mechanical hyperalgesia had more pain on movement. Conclusions Both PCEA and NSAID+IV-PCA morphine provided sufficient analgesia with little persistent pain compared with the incidence of persistent pain in the control group. High quality acute pain management and follow-up continuing after discharge could be more important than the analgesic method per se in preventing persistent post-thoracotomy pain. In the acute phase the measurement of pain when coughing and the duration of pain after coughing could be easy measures to recognize patients having a higher risk for persistent post-thoracotomy pain. Implications To prevent persistent post-thoracotomy pain, the extended protocol for high quality pain management in hospital covering also the sub-acute phase at home, is important. This study also provides some evidence that safe and effective alternatives to thoracic epidural analgesia do exist. The idea to include the standard "as usual" care patients as a control group and to compare them with the intervention patients provides valuable information of the added value of being a study patient, and deserves further consideration in future studies.
开胸手术可导致严重疼痛,21% - 67%的患者疼痛会持续存在。我们研究了非甾体抗炎药(NSAID)联合静脉自控镇痛(IV - PCA)使用吗啡是否是胸段硬膜外镇痛(TEA)的有效替代方法。我们还想了解临床研究中扩展的疼痛控制管理方案是否能降低开胸术后持续性疼痛的发生率。方法:30例开胸手术患者被随机分为3个干预组,每组10例。G1组:术前口服双氯芬酸75mg + 术后44小时静脉注射150mg/24小时,之后改为口服;G2组:术前口服伐地昔布40mg + 术后44小时静脉注射帕瑞昔布80mg/24小时,之后改为口服。G1组和G2组在胸腔引流期间可使用IV - PCA吗啡,且在手术结束时进行肋间神经阻滞;G3组:对乙酰氨基酚 + 患者自控硬膜外镇痛(PCEA),背景输注布比卡因加芬太尼。PCA/PCEA结束后,必要时给予口服羟考酮。在出院后1周、3个月和6个月对这些患者进行随访。111例未参与该研究的患者按照医院常规治疗作为对照组。提取对照组患者围手术期的数据,并向其邮寄一份与干预组类似的术后6个月前瞻性随访问卷。结果:由于伐地昔布全面撤市,干预组未达到预定样本量,研究提前终止。6个月时,3%的干预组患者和24%的对照组患者报告有持续性疼痛(p<0.01)。双氯芬酸和伐地昔布提供的镇痛效果相似,在联合NSAID组(双氯芬酸 + 伐地昔布)中,与NSAID组相比,PCEA组与活动相关的疼痛更轻。与NSAID + IV - PCA组相比,PCEA组咳嗽后疼痛持续时间更短。术后6个月唯一有持续性疼痛的患者咳嗽后疼痛持续时间比其他研究患者长得多。有机械性痛觉过敏的患者活动时疼痛更明显。结论:与对照组持续性疼痛的发生率相比,PCEA和NSAID + IV - PCA吗啡均提供了足够的镇痛效果,且持续性疼痛较少。高质量的急性疼痛管理及出院后持续的随访在预防开胸术后持续性疼痛方面可能比镇痛方法本身更重要。在急性期,咳嗽时疼痛的测量及咳嗽后疼痛的持续时间可能是识别开胸术后持续性疼痛高风险患者的简便方法。启示:为预防开胸术后持续性疼痛,在医院实施涵盖家庭亚急性期的高质量疼痛管理扩展方案很重要。本研究还提供了一些证据,表明确实存在胸段硬膜外镇痛的安全有效替代方法。将标准“常规”护理患者纳入对照组并与干预组患者进行比较的想法,为作为研究对象的附加价值提供了有价值的信息,值得在未来研究中进一步考虑。